George Tachas

George Tachas serves as the Chief Scientific Officer at Myopharm Limited, where responsibilities include developing innovative treatments for diabetes and metabolic diseases, with a focus on the commercialization of TriGlytza(R). Prior to this role, George operated as a Principal Scientist at Percheron Therapeutics Limited and held the position of Director of Drug Discovery and Patents at Antisense Therapeutics Ltd from 2001 until February 2024. George earned a Ph.D. in Science from the University of Melbourne, attended from 1980 to 1988.